Schroder Investment Management Group
ARQT icon

Schroder Investment Management Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Schroder Investment Management Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79M Hold
104,356
– – ﹤0.01% 865
2026
Q1 		$2.23M Buy
104,356
+47,220
+83% +$1.21M ﹤0.01% 907
2025
Q4 		$1.6M Buy
57,136
+594
+1% +$15.2K ﹤0.01% 919
2025
Q3 		$1.05M Buy
+56,542
New +$892K ﹤0.01% 1016
2024
Q3 		– Sell
-221,697
Closed -$2.06M – 1202
2024
Q2 		$2.06M Buy
221,697
+203,562
+1,122% +$1.84M ﹤0.01% 925
2024
Q1 		$180K Buy
18,135
+6,737
+59% +$50.3K ﹤0.01% 1177
2023
Q4 		$34.4K Hold
11,398
– – ﹤0.01% 1178
2023
Q3 		$63.6K Buy
+11,398
New +$96.9K ﹤0.01% 1184

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Schroder Investment Management Group's ARQT Position: Q2 2026 in Review

Schroder Investment Management Group held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 104,356 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #865.

Schroder Investment Management Group first reported a position in ARQT in Q3 2023 and has held it in 8 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Schroder Investment Management Group held 104,356 shares of Arcutis Biotherapeutics worth $2.79M as of Q2 2026.
  • Schroder Investment Management Group left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #865 holding.
  • Schroder Investment Management Group first reported a position in Arcutis Biotherapeutics in Q3 2023 and has held it in 8 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.